Sorrento Reports Promising Results With a Universal Chimeric mRNA COVID-19 Vaccine That Elicits Potent Neutralizing Antibodies and Protection Against Omicron (BA.1 and BA.2) and Delta Variants

Written by Customer Service on March 20, 2022. Posted in Public Companies.

Sorrento scientists have perfected the expression of the spike protein to potentially improve the safety profile of the COVID-19 mRNA vaccines by incorporating a furin cleavage site mutation to prevent leakage of S1 subunit into the blood circulation targeting vital organ tissues with ACE2 receptors for the spike proteins that may in part cause the undesirable side effects. Sorrento’s designer mRNA vaccine, utilizing a chimeric mRNA that incorporates the Delta receptor binding domain (RBD) into the Omicron spike protein, provided strong, broad-spectrum protection against both BA.1 and BA.2 sublineages of Omicron, and Delta variant in immunized animals. Sorrento intends to develop and seek EUA approval of this next-generation mRNA vaccine in Mexico and other developing countries. SAN DIEGO, March 20, 2022 (GLOBE NEWSWIRE) — Sorrento...

Imperial Petroleum Announces Pricing of Upsized $60 Million Underwritten Public Offering

Written by Customer Service on March 20, 2022. Posted in Public Companies.

ATHENS, Greece, March 20, 2022 (GLOBE NEWSWIRE) — Imperial Petroleum Inc. (Nasdaq: IMPP) (the “Company”) announced today the pricing of an upsized underwritten public offering of 37,500,000 units at a price of $1.60 per unit. Each unit consists of one common share (or prefunded warrant in lieu thereof) and one Class B warrant to purchase one common share, and will immediately separate upon issuance. The gross proceeds of the offering to the Company, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $60 million. The Company intends to use the net proceeds of the offering for capital expenditures, including acquisitions of additional vessels which we have not yet identified, and for other general corporate purposes. Each Class B warrant is immediately exercisable for one...

Barrick, Pakistan and Balochistan Agree in Principle to Restart Reko Diq Project

Written by Customer Service on March 20, 2022. Posted in Public Companies.

ISLAMABAD, Pakistan, March 20, 2022 (GLOBE NEWSWIRE) — Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) and the governments of Pakistan and Balochistan have reached agreement on a framework that provides for the reconstitution of the Reko Diq project in the country’s Balochistan province. The project, which was suspended in 2011 due to a dispute over the legality of its licensing process, hosts one of the world’s largest undeveloped open pit copper-gold porphyry deposits. The reconstituted project will be held 50% by Barrick and 50% by Pakistan stakeholders, comprising a 10% free-carried, non-contributing share held by the government of Balochistan, an additional 15% held by a special purpose company owned by the government of Balochistan and 25% owned by other federal state-owned enterprises. A separate agreement provides for Barrick’s...

Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ Congress

Written by Customer Service on March 20, 2022. Posted in Public Companies.

BOTHELL, Wash., March 20, 2022 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that study overview and baseline data from ACT-AD, a fully enrolled Phase 2 clinical trial of Athira’s lead development candidate, fosgonimeton (ATH-1017) in study participants with mild-to-moderate Alzheimer’s disease (AD), were presented in an oral presentation at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Diseases (AD/PD™ 2022) taking place in Barcelona, Spain, and virtually from March 15-20, 2022. Of the 77 study participants enrolled in the randomized, double-blind, placebo-controlled trial, the mean age is 71.4 years, with 50.6% female...

M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31

Day: March 20, 2022